Adeno-Associated Virus Mediated Gene Therapy for Corneal Diseases
Open Access
- 13 August 2020
- journal article
- review article
- Published by MDPI AG in Pharmaceutics
- Vol. 12 (8) , 767
Abstract
According to the World Health Organization, corneal diseases are the fourth leading cause of blindness worldwide accounting for 5.1% of all ocular deficiencies. Current therapies for corneal diseases, which include eye drops, oral medications, corrective surgeries, and corneal transplantation are largely inadequate, have undesirable side effects including blindness, and can require life-long applications. Adeno-associated virus (AAV) mediated gene therapy is an optimistic strategy that involves the delivery of genetic material to target human diseases through gene augmentation, gene deletion, and/or gene editing. With two therapies already approved by the United States Food and Drug Administration and 200 ongoing clinical trials, recombinant AAV (rAAV) has emerged as the in vivo viral vector-of-choice to deliver genetic material to target human diseases. Likewise, the relative ease of applications through targeted delivery and its compartmental nature makes the cornea an enticing tissue for AAV mediated gene therapy applications. This current review seeks to summarize the development of AAV gene therapy, highlight preclinical efficacy studies, and discuss potential applications and challenges of this technology for targeting corneal diseases.Keywords
This publication has 143 references indexed in Scilit:
- Production of Recombinant Adeno‐Associated Viral Vectors and Use in In Vitro and In Vivo AdministrationCurrent Protocols in Neuroscience, 2011
- Anti-apoptotic gene therapy prolongs survival of corneal endothelial cells during storageGene Therapy, 2011
- Long-term Amelioration of Feline Mucopolysaccharidosis VI After AAV-mediated Liver Gene TransferMolecular Therapy, 2011
- AAV serotype influences gene transfer in corneal stroma in vivoExperimental Eye Research, 2010
- A viral assembly factor promotes AAV2 capsid formation in the nucleolusProceedings of the National Academy of Sciences, 2010
- Self-complementary AAV Virus (scAAV) Safe and Long-term Gene Transfer in the Trabecular Meshwork of Living Rats and MonkeysInvestigative Ophthalmology & Visual Science, 2010
- Reducing the Risk of Adeno-Associated Virus (AAV) Vector Mobilization with AAV Type 5 VectorsJournal of Virology, 2009
- Functions of ocular surface mucins in health and diseaseCurrent Opinion in Allergy and Clinical Immunology, 2008
- Gene therapy for haemophiliaBritish Journal of Haematology, 2008
- The keratocyte: Corneal stromal cell with variable repair phenotypesThe International Journal of Biochemistry & Cell Biology, 2006